Report Scope:
This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).
This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.
This report, however, does not cover epigenetic diagnostic assays and instruments.
Report Includes:
- 77 tables
- A comprehensive overview of the global markets for epigenetic therapeutics
- Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
- In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
- Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
- A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
- Review of patent trends and research publications for innovations in the genome-editing technologies
- Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
- Analysis of the competitive environment and market opportunities based on the company's business strategies, product mapping, and operational integration
- Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte
Summary:
The global epigenetic therapeutics market was valued at $REDACTED billion in 2022. The market is expected to reach $REDACTED billion by 2028, growing at a compound annual growth rate (CAGR) of REDACTED% over the forecast period. Growth factors include aging populations, increased frequency of cancer risk associated with aging and increased prevalence of cancers cases such as acute-T-cell leukemia, breast cancer, ovarian cancer, Non-Small-Cell lung cancers. Epigenetic drug therapy serves as an ultimate treatment option when a cancer patient is not responding to the conventional therapies such as chemotherapy.
Technological innovations in epigenetic drug discovery and development are driving increased use of epigenetic therapeutics, which also is pushing market growth. However, loss of exclusivity in the case of a few branded drugs and the entry of generic drugs into the market is the restraining the growth of this market.
In 2022, the PRAP inhibitors segment held the largest share of the global market for epigenetic therapeutics, with REDACTED% of the market, followed by Kinase inhibitors (REDACTED%), HDAC inhibitors (REDACTED%), IDH inhibitors (REDACTED%), DNMT inhibitors (REDACTED%) and KMT inhibitors (REDACTED%)
Epigenetic Therapeutics: Global Markets
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Highlights of the Market for Epigenetic Therapeutics
Chapter 3 Market Overview and Definitions
Overview
Epigenetics
Chapter 4 Market Trends
Market Drivers
Aging Population
Risk of Cancer in Major Countries
Penetration of Targeted Medicine in Emerging Markets
Market Opportunity
Market Restraints
Chapter 5 Market Breakdown by Product Type
Introduction
PRAP Inhibitors
Kinase Inhibitors
IDH Inhibitors
HDAC Inhibitors
DNMT Inhibitors
KMT Inhibitors
Chapter 6 Impact of COVID-19
Introduction
Impact of COVID-19 on the Medical Devices and Pharmaceutical Industries
Decline/Delay in Elective Procedures
Impact of COVID-19 on Medical Device and Pharmaceutical Product Segments
Impact of COVID-19 on Epigenetic Therapeutics Markets
Chapter 7 Market Breakdown by Region
Market Overview and Discussion
North America
Latin America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Emerging/Upcoming Technologies
CRISPR
Antibody Drug Conjugates
Multitargeting Agents
Chapter 9 Competitive Landscape
Industry Scenario
Company Shares
Chapter 10 Patent Analysis
Patent Analysis, by Manufacturer
Chapter 11 Pipeline Analysis
Clinical Trials Scenario
Chapter 12 Company Profiles
ASTRAZENECA
BRISTOL-MYERS SQUIBB
CLOVIS ONCOLOGY
GSK PLC
INCYTE
IPSEN
SEAGEN
SERVIER LABORATORIES, LTD.
Chapter 13 Appendix: Acronyms
List of Tables
Summary Table : Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 1 : Global Population, Age 60 and Older, 2010-2050
Table 2 : Incidence of Pancreas Cancer, 2020-2040
Table 3 : Incidence of Trachea, Bronchus and Lung Cancer, 2020-2040
Table 4 : Incidence of Melanoma Cancer, 2020-2040
Table 5 : Incidence of Prostate Cancer, 2020-2040
Table 6 : Incidence of Breast Cancer, 2020-2040
Table 7 : Incidence of Kidney and Renal Pelvis Cancers, 2020-2040
Table 8 : Incidence of Hodgkin Lymphoma Cancer, 2020-2040
Table 9 : Incidence of Non-Hodgkin Lymphoma Cancer, 2020-2040
Table 10 : Incidence of Multiple Myeloma and Immunoproliferative Diseases, 2020-2040
Table 11 : Incidence of Leukemia Cancer, 2020-2040
Table 12 : Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 13 : Global PRAP Inhibitors Market, by Region, Through 2028
Table 14 : Global Kinase Inhibitors Market, by Region, Through 2028
Table 15 : Global IDH Inhibitors Market, by Region, Through 2028
Table 16 : Global HDAC Inhibitors Market, by Region, Through 2028
Table 17 : Global DNMT Inhibitors Market, by Region, Through 2028
Table 18 : Global KMT Inhibitors Market, by Region, Through 2028
Table 19 : Global Epigenetic Therapeutics Market, by Region, Through 2028
Table 20 : North American Epigenetic Therapeutics Market, by Country, Through 2028
Table 21 : Latin American Epigenetic Therapeutics Market, by Country, Through 2028
Table 22 : European Epigenetic Therapeutics Market, by Country, Through 2028
Table 23 : Asia-Pacific Epigenetic Therapeutics Market, by Country, Through 2028
Table 24 : RoW Epigenetic Therapeutics Market, Through 2028
Table 25 : Patents on Epigenetic Drugs, 2015-April 2023
Table 26 : Selected Manufacturer Patents on Epigenetic Drugs, 2015-April 2023
Table 27 : Patents on HDAC Inhibitors, 2015-April 2023
Table 28 : Selected Manufacturer Patents on HDAC inhibitors, 2015-April 2023
Table 29 : Patents on Kinase inhibitors, 2015-April 2023
Table 30 : Patents on Verinostat Drug, 2015-April 2023
Table 31 : Selected Manufacturer Patents on Verinostat Drug, 2015-April 2023
Table 32 : Patents on Romidepsin Drug, 2015-April 2023
Table 33 : Selected Manufacturer Patents on Romidepsin Drug, 2015-April 2023
Table 34 : Patents on Panobinostat Drug, 2015-April 2023
Table 35 : Selected Manufacturer Patents on Panobinostat Drug, 2015-April 2023
Table 36 : Patents on Belinostat, 2015-April 2023
Table 37 : Selected Manufacturer Patents on Belinostat, 2015-April 2023
Table 38 : Patents on Tucidinostat Drug, 2015-April 2023
Table 39 : Selected Manufacturer Patents on Tucidinostat Drug, 2015-April 2023
Table 40 : Patents on 5-Azacytidine Drug, 2015-April 2023
Table 41 : Selected Manufacturer Patents on 5-Azacytidine Drug, 2015-April 2023
Table 42 : Patents on 5-Aza-2'-Deoxycytidine Drug, 2015-April 2023
Table 43 : Selected Manufacturer Patents on 5-Aza-2'-Deoxycytidine Drug, 2015-April 2023
Table 44 : Patents on Pinometostat Drug, 2015-April 2023
Table 45 : Selected Manufacturer Patents on Pinometostat Drug, 2015-April 2023
Table 46 : Patents on Ruxolitinib Drug, 2015-April 2023
Table 47 : Selected Manufacturer Patents on Ruxolitinib Drug, 2015-April 2023
Table 48 : Patents on AZD1152 Drug, 2015-April 2023
Table 49 : Selected Manufacturer Patents on AZD1152 Drug, 2015-April 2023
Table 50 : Patents on Olaparib Drug, 2015-April 2023
Table 51 : Selected Manufacturer Patents on Olaparib Drug, 2015-April 2023
Table 52 : Patents on Veliparib Drug, 2015-April 2023
Table 53 : Selected Manufacturer Patents on Veliparib Drug, 2015-April 2023
Table 54 : Patents on Niraparib Drug, 2015-April 2023
Table 55 : Selected Manufacturer Patents on Niraparib Drug, 2015-April 2023
Table 56 : Patents on Rucaparib Drug, 2015-April 2023
Table 57 : Selected Manufacturer Patents on Rucaparib Drug, 2015-April 2023
Table 58 : Patents on Talazoparib Drug, 2015-April 2023
Table 59 : Selected Manufacturer Patents on Talazoparib Drug, 2015-April 2023
Table 60 : Selected Kinase Inhibitors in Clinical Trials, as of 2023
Table 61 : Selected Olaparib Inhibitors in Clinical Trials, as of 2023
Table 62 : Selected Romidepsin Inhibitors in Clinical Trials, as of 2023
Table 63 : Selected Ruxolitinib Inhibitors in Clinical Trials, as of 2023
Table 64 : AstraZeneca: Company Annual Revenue, 2019-2022
Table 65 : AstraZeneca: Annual Revenue, by Product, 2022
Table 66 : Bristol-Myers Squibb: Company Annual Revenue, 2019-2022
Table 67 : Clovis Oncology: Revenue, 2019-2021
Table 68 : GSK: Company Annual Revenue, 2019-2022
Table 69 : GSK: Annual Revenue, by Product, 2022
Table 70 : Incyte: Company Annual Revenue, 2019-2021
Table 71 : Incyte: Product Revenue, 2019-2021
Table 72 : Ipsen: Sales Revenue, 2021 and 2022
Table 73 : Ipsen: Sales Revenue, by Segment, 2021 and 2022
Table 74 : Ipsen: Sales Revenue, by Region, 2021 and 2022
Table 75 : Seagen: Company Annual Revenue, 2019-2021
Table 76 : Acronyms Used in this Report
List of Figures
Summary Figure A : Global Epigenetic Therapeutics Market, by Product Type, 2019-2028
Summary Figure B : Global Epigenetic Therapeutics Market Share, by Product Type, 2022
Figure 1 : Global Epigenetic Therapeutics Market, by Product, 2020-2028
Figure 2 : Global Epigenetic Therapeutics Market Share, by Product, 2022
Figure 3 : Global PRAP Inhibitors Market, by Region, 2020-2028
Figure 4 : Global PRAP Inhibitors Market Share, by Region, 2022
Figure 5 : Global Kinase Inhibitors Market, by Region, 2020-2028
Figure 6 : Global Kinase Inhibitors Market Share, by Region, 2022
Figure 7 : Global IDH Inhibitors Market, by Region, 2020-2028
Figure 8 : Global IDH Inhibitors Market Share, by Region, 2022
Figure 9 : Global HDAC Inhibitors Market, by Region, 2020-2028
Figure 10 : Global HDAC Inhibitors Market Share, by Region, 2022
Figure 11 : Global DNMT Inhibitors Market, by Region, 2020-2028
Figure 12 : Global DNMT Inhibitors Market Share, by Region, 2022
Figure 13 : Global KMT Inhibitors Market, by Region, 2020-2028
Figure 14 : Global KMT Inhibitors Market Share, by Region, 2022
Figure 15 : Global Epigenetic Therapeutics Market Share, by Region, 2022
Figure 16 : North American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 17 : Latin American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 18 : European Epigenetic Therapeutics Market Share, by Country, 2022
Figure 19 : Asia-Pacific Epigenetic Therapeutics Market Share, by Country, 2022
Figure 20 : Global Epigenetic Therapeutics Market Share, by Company, 2022
Figure 21 : Global PRAP Inhibitors Market Share, by Company, 2022
Figure 22 : Global Kinase Inhibitors Market Share, by Company, 2022
Figure 23 : Global IDH Inhibitors Market Share, by Company, 2022
Figure 24 : Global HDAC Inhibitors Market Share, by Company, 2022
Figure 25 : Global DNMT Inhibitors Market Share, by Company, 2022
Figure 26 : Global KMT Inhibitors Market Share, by Company, 2022
Figure 27 : AstraZeneca: Sales Share, by Product, 2022
Figure 28 : AstraZeneca: Sales Share, by Region, 2022
Figure 29 : Bristol-Myers Squibb: Sales Share, by Region, 2022
Figure 30 : GSK: Revenue Share, by Product, 2022
Figure 31 : GSK: Sales Share, by Region, 2022
Figure 32 : Ipsen: Sales Revenue Share, by Segment, 2022
Figure 33 : Ipsen: Sales Revenue Share, by Region 2022
Global Genome Editing Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 16-Nov-2023 Price: US 3380 Onwards Pages: 111
Market Overview of Global Genome Editing market:
According to our latest research, the global Genome Editing market looks promising in the next 5 years. As of 2022, the global Genome Editing market was estimated at USD 7377.87 million, and it's anticipated to reach USD 25474.29 million in 2028, with a CAGR of 22.94% during the forecast years.
Genome editing is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organ......
Global Genome Editing Market Insights, Forecast to 2029
Published: 14-Aug-2023 Price: US 4900 Onwards Pages: 86
Genome editing, or genome engineering is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in target......
Animal Genetics Market by Product (Live Animal (Poultry, Porcine, Bovine, Canine) Genetic Material (Semen (Bovine, Porcine, Equine), Embryo (Bovine, Equine)) Genetic Testing Service (Disease, Genetic Traits - Bovine, DNA Typing)) - Global Forecast to 2028
Published: 10-Aug-2023 Price: US 4950 Onwards Pages: 320
Rising demand for livestock animals due to the growing population, increasing per capita income, and rapid urbanization will drive the market growth.
The global animal genetics market is projected to reach USD 9.5 billion by 2028 from USD 6.6 billion in 2023, at a CAGR of 7.4% during the forecast period. The increasing consumption of animal products, adoption of advanced genetic testing methods, animal welfare activities, and demand for companion animals are fueling the growth of this......
Epigenetic Therapeutics: Global Markets
Published: 01-Jun-2023 Price: US 5500 Onwards Pages: 155
Report Scope:
This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).
......
Genome Editing Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030
Published: 05-May-2023 Price: US 4150 Onwards Pages: 146
The study predicts the short term and long term trends that can shape up the future of the Genome Editing market including the COVID-19 pandemic implications for Genome Editings industry. The report presents market size forecasts across types, applications, end users and countries across regions. Strategic imperatives for development managers, decision makers and industry professionals including market trends, drivers, challenges, five forces analysis, insights on markets and companies.
......
Global Genome Editing Market Insights: Impact of COVID-19 and Future Expectations to 2028
Published: 16-Mar-2023 Price: US 3260 Onwards Pages: 95
Genome editing is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
The Genome Editing market revenue was 7377.87 Million USD in 2022, and will reach 25474.29 Million USD in 2028, with a CAGR of 22.94% during 2022-2028.
This report elabo......
Global Genome Editing/Genome Engineering Market Status and Outlook 2023-2028
Published: 01-Mar-2023 Price: US 3160 Onwards Pages: 108
Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging ......
Global Genome Engineering Market Status and Outlook 2023-2028
Published: 23-Feb-2023 Price: US 3160 Onwards Pages: 107
Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in......
Global Genome Editing Market Research Report 2023
Published: 07-Feb-2023 Price: US 2900 Onwards Pages: 85
Genome editing, or genome engineering is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in target......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
